Oncologic Accelerated Approval Phase IV Studies For 7 Drugs To Be Reviewed
Executive Summary
Accelerated approval Phase IV commitments for seven oncologic products will be reviewed at the March 12-13 meeting of FDA's Oncologic Drugs Advisory Committee